Score Overview
Explore the 2021 public Archive ranking →
Where Cellectar Biosciences Inc has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 30 years of fundamentals. CLRB does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-30 | $ 1.84 | — |
1 Year2025-09-30 | $ 5.60 | -67.14% |
5 Years2021-09-30 | $ 277.50 | -99.34% |
10 Years2016-09-30 | $ 8.13K | -99.98% |
20 Years2006-09-29 | $ 1000K | -100.00% |
All Time2005-11-10 | $ 1000K | -100.00% |
| Period | Last Price2026-09-30 | 1 Year2025-09-30 | 5 Years2021-09-30 | 10 Years2016-09-30 | 20 Years2006-09-29 | All Time2005-11-10 |
|---|---|---|---|---|---|---|
| Price | $ 1.84 | $ 5.60 | $ 277.50 | $ 8.13K | $ 1000K | $ 1000K |
| Return | — | -67.14% | -99.34% | -99.98% | -100.00% | -100.00% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 0.00 | -$ 20M | $ 8M |
| 2025 | $ 0.00 | -$ 21M | $ 13M |
| 2024 | $ 0.00 | -$ 44M | $ 23M |
| 2023 | $ 0.00 | -$ 42M | $ 9M |
| 2022 | $ 0.00 | -$ 28M | $ 19M |
| 2021 | $ 0.00 | -$ 23M | $ 35M |
| 2020 | $ 0.00 | -$ 15M | $ 57M |
| 2019 | $ 0.00 | -$ 14M | $ 10M |
| 2018 | $ 0.00 | -$ 13M | $ 13M |
| 2017 | $ 0.00 | -$ 13M | $ 10M |
| 2016 | $ 0.00 | -$ 6M | $ 11M |
| 2015 | $ 0.00 | -$ 5M | $ 3M |
| 2014 | $ 0.00 | -$ 8M | $ 9M |
| 2013 | $ 0.00 | -$ 10M | $ 2M |
| 2012 | $ 0.00 | -$ 8M | $ 4M |
| 2011 | -$ 11K | -$ 7M | $ 5M |
| 2010 | $ 33.33K | $ 2M | $ 2M |
| 2009 | $ 96.31K | -$ 22M | $ 8M |
| 2008 | $ 125.97K | -$ 16M | $ 1M |
| 2007 | -$ 19M | $ 9M | |
| 2006 | $ 12.58K | -$ 8M | $ 9M |
| IPO2005 | $ 12.58K | -$ 3M | $ 4M |
Cellectar Biosciences Inc fundamental performance
Between 2005 and 2025, revenue declined from $ 12.58K to $ 0.00 and net income went from -$ 3M to -$ 21M. Revenue increased in 1 of those 20 years; net income in 7.
Cellectar Biosciences Inc currently holds a 20-year HDB Score of 1.3 out of 10. How the HDB Score is calculated.
Membership
Explore CLRB with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
